PTC Therapeutics Inc (PTCT)
PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of medicines. Co. has a portfolio pipeline that includes several commercial products and product candidates focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology, metabolism and oncology. Co. has two products, Translarna (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy, or DMD. Translarna is designed for the treatment of nonsense mutation DMD in ambulatory patients aged two years and older Emflaza is designed for the treatment of DMD in patients two years and older.
PTCT SEC Filing Email Alerts Service
Company Name: |
PTC Therapeutics Inc |
Website: |
www.ptcbio.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding PTCT: |
36 |
Total Market Value Held by ETFs: |
$398.12M |
Total Market Capitalization: |
$2.21B |
% of Market Cap. Held by ETFs: |
18.01% |
|
|
March 28, 2024 7:55 AM Eastern
Hold (2.16 out of 4)
0th percentile
|
|